69 results
PRE 14A
ALBT
Avalon GloboCare Corp
29 Aug 23
Preliminary proxy
4:55pm
American: BTX), a clinical stage regenerative medicine company with a focus on pluripotent stem cell technology. Dr. Jin also acts as a senior translational
8-K
EX-99.1
ALBT
Avalon GloboCare Corp
27 Apr 23
Avalon GloboCare Reports Laboratory Services MSO Revenue of $14.7 Million and Net Income of $6.3 Million in 2022
4:26pm
™), and regenerative therapeutics. For more information about Avalon GloboCare, please visit www.avalon-globocare.com.
For the latest updates
8-K
EX-99.1
t5lww0mcrrg70yw h7
14 Dec 22
Entry into a Material Definitive Agreement
9:18am
DEFA14A
pt3bcf96u alj
12 Dec 22
Additional proxy soliciting materials
10:41am
8-K
EX-99.1
ihiqlfk6i22uqgvqns
8 Nov 22
Entry into a Material Definitive Agreement
9:15am
8-K
EX-99.1
ys7 b881kcp5loxrnfpo
4 Jan 22
Avalon GloboCare Provides Year-End Business Update of Selective Scientific and Clinical Programs
9:05am
8-K
EX-99.1
asrun11 91msq2tl5
22 Dec 21
Entry into a Material Definitive Agreement
11:17am